vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: Vedolizumab is a gut-selective monoclonal antibody that acts as an integrin antagonist by binding to α4β7 integrins on the surface of gastrointestinal-homing T lymphocytes.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
PB016 n/aPolpharma Biologics/Fresenius KabiPhase 3moderate-severe active ulcerative colitis and Crohn's disease
Click here for help
Immunopharmacology Comments
Vedolizumab blocks the interaction between α4β7 integrins and MAdCAM-1. This disrupts inflammatory lymphocyte ingress into gastrointestinal tissue.
Immunopharmacology Disease
Disease X-Refs Comment References
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
Approved therapeutic for CD.
Ulcerative colitis Disease Ontology: DOID:8577
OMIM: 266600
Orphanet: ORPHA771
Approved therapeutic for UC.